Prevalence and opinions of hormone therapy prior to the women's health initiative: A multinational survey on four continents

Journal of Women's Health

Volumn 17, Issue 7, 2008, Pages 1151-1166

  Heinemann, Klaas ^a   Rübig, Alexander ^b   Strothmann, Anja ^c   Nahum, Gerard G ^d,e   Heinemann, Lothar A J ^f  

^a BAYER PHARMA AG   (Germany)

^b Bayer SA Chile Santiago de Chile

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e BAYER CORPORATION   (United States)

^f Berlin Center for Epidemiology and Health Research   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ADULT; AGED; ARTICLE; FEMALE; FRANCE; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; INDONESIA; MENOPAUSAL SYNDROME; MOTIVATION; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; QUOTA SAMPLE; SELF REPORT; SOUTH AND CENTRAL AMERICA; WOMEN'S HEALTH;

ADULT; AGED; CROSS-CULTURAL COMPARISON; DECISION MAKING; ESTROGEN REPLACEMENT THERAPY; EUROPE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HOT FLASHES; HUMANS; INDONESIA; LATIN AMERICA; MENOPAUSE; MIDDLE AGED; PREVALENCE; SEVERITY OF ILLNESS INDEX; UNITED STATES; WOMEN'S HEALTH;

EID: 51349162957     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0584     Document Type: Article

References (32)

1. Manson JE, Hsia J, Johnson KC, et al., for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
2. Rossouw JE, Anderson GL, Prentice RL, et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Wassertheil-Smoller S, Hendrix SL, Limacher Marian, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: A randomized trial. JAMA 2003;289:2673-2684.
4. Rapp SR, Espeland MA, Shumaker SA, et al., for the WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. JAMA 2003;289:2663-2672.
5. Beral V, Banks E, Reeves G. Evidence from randomized trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944.
6. Potthoff P, Heinemann LAJ, Güther B. A household panel as a tool for cost-effective health-related population surveys: Validity of the "Healthcare Access Panel." German Med Sci 2004;2:Doc05. Available at www.egms.de
7. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale: A methodological review. Health Qual Life Outcomes 2004;2:45. Available at www.hqlo.com/content/2/1/67
8. Genazzani AR, Nicolucci A, Campagnoli C, et al. Assessment of the QoL in Italian menopausal women: Comparison between HT users and non-users. Maturitas 2002;42:267-280.
9. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
10. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996;87(Suppl 2):36-43.
11. Calafi Alsina J. Benefits of hormone replacement therapy - Overview and update. Int J Fertil Womens Med 1997; 42(Suppl 2):329-346.
12. Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med 2002;162:1934-1942.
13. Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 1997;103:11-17.
14. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
15. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-3263.
16. Whitehead M, Farmer R. The Million Women Study: A critique. Endocrine 2004;24:187-193.
17. Shapiro S. Risks of estrogen plus progestin therapy: A sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;6:302-310.
18. Shapiro S. The Million Women Study: Potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7.
19. Naftolin F, Taylor H, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004;81:1498-1501.
20. Garbe E, Suissa S. Hormone replacement therapy and acute coronary outcomes: Methodological issues between randomized and observational studies. Hum Reprod 2004;19:8-13.
21. Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: An epidemiological dilemma? Hum Reprod 2003;18:1992-1999.
22. Shaffler LE, Krantz CA. Hormone therapy and cardiovascular risk. JAMA 2007;298:623-624.
23. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K, WHO MONICA Project. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 2004;48:39-49.
24. Gold EB, Block G, Crawford S, et al. Lifestyle and demographic factors in relation to vasomotor symptoms: Baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol 2004;159:1189-1199.
25. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226-1235.
26. Schneider HPG. Cross-national study of women's use of hormone replacement therapy (HT) in Europe. Int J Fertil Womens Med 1997;42(Suppl 2):365-375.
27. Thiel C, Heinemann LAJ, Assmann A. Reasons for the changing use of HT from the perspective of women. Results of the German Cohort Study on Women's Health. Zent Gynäk 2001;123:390-398.
28. Buist D, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-1050.
29. Strothmann A, Schneider HPG. Hormone therapy: The European women's perspective. Climacteric 2003;6:337-346.
30. Strothmann A., Schneider HPG, Schaefer M. Hormone therapy: The U.S. women's perspective. Presented at 16th Annual Meeting of the North American Menopause Society (NAMS), September 2005.
31. Vihtamäki T, Savilahti R, Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 1999;33:99-105.
32. Schneider HPG, Dören M. Traits for long-term acceptance of hormone replacement therapy - results of a representative German survey. Eur Menopause J 1996;3:94-98.